Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH-6003 injection for cerebral edema after intracerebral hemorrhage (Phase II)
CTR20232769Phase 2Active
- Sponsor
- Shanghai Xunhe Pharmaceutical Technology Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JRF102 in cerebral edema, intracerebral hemorrhage (ICH), sponsored by Shanghai Xunhe Pharmaceutical Technology Co., Ltd.. Started Sep 2023; status: active.
02
Drugs
JRF102
03
Conditions
cerebral edemaintracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on CTR20232769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232769.